ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1190

Sex Differences in Cardiovascular Disease Prevention in Patients with Rheumatoid Arthritis: World-wide Data from the SURF-RA

Elena Myasoedova1, Cynthia Crowson2, Joseph Sexton3, Silvia Rollefstad3 and Anne Grete Semb4, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, 3Diakonhjemmet Hospital, Oslo, Norway, 4Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway

Meeting: ACR Convergence 2020

Keywords: Cardiovascular, prevention, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III: Cardiopulmonary Aspects

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is associated with 2-fold increase in risk of cardiovascular (CV) disease. Extensive evidence from the general population suggests that control of CV risk factors helps in reducing CV morbidity and mortality. However, CV risk factor screening and management has been suboptimal both in the general population and in patients with RA. We aimed to establish whether there is a difference in CV risk factor screening and control of CV risk factors in RA by sex globally, and whether RA characteristics affect the likelihood of CV screening in women and men.

Methods: The SUrvey of cardiovascular disease Risk Factor management in Rheumatoid Arthritis (SURF-RA) is an international clinical audit. The data were collected from rheumatology and cardiology clinics in Western and Eastern Europe, North and Latin America and Asia, using a one-page collection sheet. Information on demographics, CV risk factors (i.e. smoking, body mass index [BMI], physical activity, lipid panel, hemoglobin A1c [HbA1c], blood pressure [BP] measurements) and RA disease characteristics (i.e. serologic status, C-reactive protein [CRP], Disease activity score using 28 joints and CRP [DAS28-CRP]) was collected. Lipid panel and HbA1c were required within 1 year of clinic visit. CV Health Index Score was calculated as a sum of controlled CV risk factors out of the following six: smoking, BMI, physical activity, BP, low density lipoprotein cholesterol (LDL-C) and HbA1c. Normal levels were defined as follows: total cholesterol < 4.5 mmol/L (< 174 mg/dL), LDL-C < 2.5 mmol/L (< 100 mg/dL), BP< 140/90 mm/Hg, HbA1c < 7.0%, BMI < 25.0 kg/m^2.

Results: A total of 14,503 patients with RA from 53 centers in 19 countries were included in the study: mean age 60 years, 75% female, 57% rheumatoid factor (RF) positive, 54% positive for antibody to cyclic citrullinated peptide (ACPA), mean DAS28-CRP 3.0. Information on CV risk factor measures by sex is shown in Table 1. No difference was observed in frequency of assessment of lipid measures, BP or HbA1c. Men were more likely to have normal total cholesterol (p< 0.0001) and LDL-C than women (p< 0.0001). In contrast, women were more likely to have normal BP (p< 0.0001) and normal HbA1c (p=0.02) than men. Women had overall better CV Health Index Score than men (p< 0.0001). Table 2 shows associations of risk factor assessment in patients with RA, adjusting for age, sex, country and ethnicity. Longer RA disease duration, positivity for RF and ACPA, higher DAS28-CRP were associated with higher likelihood of lipid and BP testing, particularly in women, but did not appear to affect the odds of HbA1c assessment.

Conclusion: Women with RA are more likely to have normal BP and HbA1c, resulting in better overall control of CV risk factors, as assessed by CV Health Index Score than men. Patients with RF and/or ACPA, longer RA duration (particularly women), as well as men and women with higher DAS28-CRP are more likely to have lipid panel and BP assessments, suggesting physician awareness of adverse CV risk profile in RA.


Disclosure: E. Myasoedova, None; C. Crowson, Myriad Genetics, 1, Pfizer, 1; J. Sexton, None; S. Rollefstad, None; A. Semb, None.

To cite this abstract in AMA style:

Myasoedova E, Crowson C, Sexton J, Rollefstad S, Semb A. Sex Differences in Cardiovascular Disease Prevention in Patients with Rheumatoid Arthritis: World-wide Data from the SURF-RA [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/sex-differences-in-cardiovascular-disease-prevention-in-patients-with-rheumatoid-arthritis-world-wide-data-from-the-surf-ra/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sex-differences-in-cardiovascular-disease-prevention-in-patients-with-rheumatoid-arthritis-world-wide-data-from-the-surf-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology